Advertisement
Advertisement

EOLS

EOLS logo

Evolus, Inc. Common Stock

4.21
USD
Sponsored
-0.17
-3.78%
Mar 26, 14:43 UTC -4
Open

EOLS Earnings Reports

Positive Surprise Ratio

EOLS beat 21 of 33 last estimates.

64%

Next Report

Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$73.73M
/
-$0.13
Implied change from Q4 25 (Revenue/ EPS)
-17.35%
/
-316.67%
Implied change from Q1 25 (Revenue/ EPS)
+7.61%
/
-13.33%

Evolus, Inc. Common Stock earnings per share and revenue

On Mar 03, 2026, EOLS reported earnings of 0.06 USD per share (EPS) for Q4 25, beating the estimate of 0.05 USD, resulting in a 17.65% surprise. Revenue reached 89.22 million, compared to an expected 91.46 million, with a -2.45% difference. The market reacted with a +2.12% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of -0.13 USD, with revenue projected to reach 73.73 million USD, implying an decrease of -316.67% EPS, and decrease of -17.35% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
logo
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
logo
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
logo
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
logo
Sanara MedTech Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.11
Actual
$0.04
Surprise
-64.35%
logo
Cytosorbents Corp.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.09
Surprise
-76.47%
logo
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
For Q4 2025, Evolus, Inc. Common Stock reported EPS of $0.06, beating estimates by 17.65%, and revenue of $89.22M, -2.45% below expectations.
The stock price moved up 2.12%, changed from $5.65 before the earnings release to $5.77 the day after.
The next earning report is scheduled for May 05, 2026.
Based on 5 analysts, Evolus, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of $73.73M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement